The blockade of EZH2 or JAM-A might have therapeutic potential by reducing T cell adhesion, migration, and extravasation in patients with lupus.43 H3K9ac, an important histone acetylation modification, is highly correlated with active promoters. The gene discussed is EZH2; the disease is systemic lupus erythematosus.